Related Experiment Videos
Review: Renal osteodystrophy--pathogenesis and treatment.
The American Journal of the Medical Sciences
|April 1, 1986
Summary
End-stage renal disease causes bone disease, including osteitis fibrosa and osteomalacia, due to altered vitamin D, calcium, phosphorus, and parathyroid hormone metabolism. Treatments for renal osteodystrophy and aluminum-associated osteomalacia are reviewed.
Area of Science:
- Nephrology
- Endocrinology
- Bone Metabolism
Background:
- Histologic bone changes like osteitis fibrosa and osteomalacia are common in end-stage renal disease (ESRD).
- These bone changes, termed renal osteodystrophy, can lead to severe disability in some ESRD patients.
- Altered metabolism of vitamin D, calcium, phosphorus, and parathyroid hormone in renal failure contributes to uremic bone disease.
Purpose of the Study:
- To review current theories on the pathogenesis and treatment of renal osteodystrophy.
- To discuss the clinical presentation, pathogenesis, and treatment of aluminum-associated osteomalacic syndromes in uremia.
Main Methods:
- Literature review of existing theories and clinical data.
- Synthesis of information on pathogenesis and treatment strategies.
Main Results:
- Uremic bone disease results from complex metabolic derangements in ESRD.
- Aluminum accumulation can cause specific osteomalacic syndromes in uremic patients.
Conclusions:
- Understanding the pathogenesis of renal osteodystrophy and aluminum-associated osteomalacia is crucial for effective management.
- Further research into treatment strategies is needed to improve outcomes for ESRD patients with bone disease.